| INTRODUC TI ON
Research from the United States, Australia, 1 Canada, 2 and European countries [3] [4] [5] [6] have shown a significant increase in opioid utilization during the past decade to such a scale that several countries (United States, Canada, Australia) have called for an organized response to the opioid crisis. [7] [8] [9] In 2017, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reports that while some parallels exist, the overall European situation remains different to that reported from the United States. 10 The highest use of (legal in and outpatient care) opioids (fentanyl, oxycodone, morphine, hydromorphone, pethidine) in 2014-2016 was documented in Germany and Austria (> 20 000 defined daily doses (DDD)/1 000 000), and this use significantly exceeds that described for the United States (16 500 DDD/1 000 000). 11 Yet, the literature highlights the absence of an opioid crisis in Germany 12 or Austria. 13 Within Europe, there is still a more than 10-fold difference between the highest consumption in the Western/Northern countries and the lowest consumption in the Southern/Eastern countries. In several countries (including Estonia) the estimated opioids use is well below 2000 DDD/1 000 000, with the lowest in the Russian Federation (135 DDD/1 000 000). 11 While high opioid usage is undoubtedly a serious problem, the underuse of opioid analgesia (low opioid prescribing) is also a threat.
Data on the use of prescription opioids dispensing and changes in use over time in Estonia are limited. 6 This study aimed to describe the trends of the most commonly prescribed opioids in Estonia from 2011 to 2017, stratified by cancer and noncancer pain treatment groups.
Abstract
Our objective was to examine the trends and variation in opioid prescribing in Estonia The use of prescription opioids is low, and raises concern about the potential undertreatment of cancer pain, in parallel with misuse of opioids for either noncancer pain or diversion.
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| MATERIAL S AND ME THODS
This time-series analysis included data on all dispensed opioids prescriptions between 2011 and 2017 in Estonia.
| Data source
Since the early 2000s, the Estonian Health Insurance Fund (EHIF)
has maintained a complete record of prescriptions issued for outpatient care. About 94% of the Estonian population is covered by the EHIF. 14 Prescriptions for uninsured individuals are also captured in the EHIF database (although not reimbursed).
| Data
We use data on all filled prescriptions for opioid analgesics (ATC 
| Utilization measures
We present (a) the number of prescriptions; (b) the number of patients; (c) the DDD 15 for each opioid per patient and/or per year;
and (d) the oral morphine equivalent (OME) 16 quantity per patient and/or per year. The annual total amount of each opioid entity dispensed was divided by the DDD of the particular opioid. 17, 18 We calculated the oral morphine equivalency to account for the variation in biological strength. The conversion to OMEs was based on the amount of the base form of the substance, according to the Summaries Product Characteristics (SmPC) 19 or by conversion factor 20 from the salt form, if the amount of the base form was not stated in the SmPC. The amount of opioid for each prescription was multiplied by the equi-analgesic ratio of the opioid to derive the OME dose. 16 
| Cancer and noncancer care use
Patients and corresponding opioid prescriptions were categorized as either 'cancer' group based on the ICD-10 codes for neoplasms (malignant, C00-C97; in situ, D00-D09; benign, D10-D36; or of uncertain or unknown behavior, D37-D48) recorded on the prescription; otherwise, they were included in the "noncancer" group. For annual comparison, each patient was again defined as "cancer" or "noncancer" according to the presence of any neoplasm diagnosis on the prescriptions in the given year.
| Data analysis
Consumption of opioids was expressed as DDD and the total annual OME in mg (for all opioids by totaling the OMEs of all opioids dispensed).
For each calendar year, we calculated the consumption of opioids expressed as DDD per 1000 population (the mid-year, Statistics We calculated the DDD per 1000 patients receiving opioids per day in outpatient care by totaling the DDDs per 1000 patients per day for each opioid.
Annual opioid prescribing rates were calculated for the total population (by dividing the number of opioid prescriptions by the total number of mid-year population) and patients (by dividing the number of opioid prescriptions by the number of patients filling prescriptions); the rates presented are per 1000 individuals. Linear trend analysis was used to assess changes in time. All analyses were conducted using statistical environment R. 22 The study procedures were conducted in accordance with local data protection regulations. The analysis used existing records containing only nonidentifiable data and was therefore exempt from ethical review.
| RE SULTS
In total, 201 890 outpatients (60% female) received opioids during the 7-year study period. Of the total opioid prescriptions, 13.8%
were filled for the management of cancer pain and 86% for noncancer pain. The mean age of patients filling opioid prescriptions (at the first prescription in the study period) was 58.8 years (SD 17.8). The patients with cancer diagnosis were older than noncancer patients (mean of 67.3 vs 57.7 years).
From 2011 to 2017, in total, 1 153 385 prescriptions of the opioid analgesics were filled. Tramadol was the most frequently used opioid (n = 699 700 prescriptions), followed by codeine (n = 338 744), oxycodone (n = 45 153), morphine (n = 32 932), dihydrocodeine (n = 22 543), fentanyl (n = 14 050), pethidine (n = 236), and very few (<25 prescriptions) for buprenorphine, tapentadole, or pethidine.
Annual opioid prescribing rates increased by 67% (from 82.9 to 138.6 prescriptions per 1000 population). When taking total oral morphine equivalency into account, the increase was sustained at 66% (from 40.0 to 66.6 g per 1000 population).
During the study period there was a 128% increase in the use of weak (codeine, dihydrocodeine, tramadol) and 164% in the use of strong opioids (morphine, oxycodone, fentanyl) ( Table 1) Table 2 ).
The annual number of prescriptions per patient did not change substantially (from 2.94 in 2011 to 2.87 in 2017) ( Table 2 ). The mean number of annual opioids prescriptions was higher among cancer patients during the period of observation (ie, 5.07 vs 2.67 annual prescriptions per cancer and noncancer patients, respectively, in 2017). In 2017 the mean annual OME for cancer patients exceeded that dispensed by noncancer patients more than four times (4600 vs 1100 mg per patient per year). The mean annual OME per cancer pain patient fluctuated from 4000 mg (in 2013) to 4900 mg (in 2016).
We did not observe a change in the annual amount of opioids (expressed in OME per patient) prescribed to noncancer patients during the period of observation.
Throughout the period, morphine consumption per patient among noncancer patients exceeded that of the cancer patients; also per patient consumption of fentanyl and dihydrocodeine was higher among noncancer patients than cancer patients in some years ( Figure 1 ).
| D ISCUSS I ON
Our study covers complete (all medical specialists) opioid analgesic prescribing (outpatient care) data for the whole of Estonia. approximately six times lower than in the United Kingdom 4 and two times lower than in Scandinavian countries. 24 At the level of outpatient care, in 2017 in Estonia the annual average opioid consumption per user was at least two to three times lower than in Scandinavian countries. 24 It is important to note that tramadol is the most used prescription opioid in Estonia. This synthetic weak μ-opioid receptor agonist was classified as a controlled substance in the United Kingdom 25 and United States 26 in 2014, and re-classification is under consideration in Canada. 27 Tramadol is not classified under controlled substances in Estonia. However, its abuse potential cannot be underestimated. 28 Second, the use of prescription opioids is increasing-we found a substantial rise in opioid prescribing between 2011 and 2017, with important differences between certain opioids. Codeine use has increased by more than 300% and use of fentanyl, oxycodone, and dihydrocodeine has increased more than 100%, whereas morphine use decreased by 7%. Increasing codeine sales have received attention in Europe in relation to abuse affecting diverse groups of patients, from children to older people and among all social classes. 29 Decreasing morphine use in parallel with the sharply increasing use of oxycodone is described in Scandinavian countries, 30, 31 the United Kingdom, 4, 17 Australia, 32 and the United States. 33 Escalating use of fentanyl for the treatment of chronic noncancer pain has also been documented elsewhere (Australia, 32 Scandinavian countries 34 ). Pharmaceutical fentanyl, with a potency 50-100 times higher than morphine, greatly increases opioid-related risks (eg, high overdose and abuse potential). [35] [36] [37] Third, irrespective of the generally low use of prescription opioids, noticeable signs should raise an alert. The role and utility of codeine and tramadol in cancer pain are controversial. 41 This epidemic of overdose mortality cannot be attributed to prescription opioids use, and was caused by the use of illicitly manufactured fentanyls (3-methylfentanyl, fentanyl, carfentanyl, narfentanyl). 42 Data from Estonia support a critical role of the illicit opioids use to the crisis.
TA B L E 1 Prescription opioids utilization
: annual prevalence, prescription rate per 1000, the number of defined daily dose (DDD) and oral morphine equivalent dose per 1000 population per year for opioids and the percentage of consumption change from 2011 to 2017 in Estonia
| CON CLUS ION
Monitoring data nationally for potentially problematic prescribing might help to highlight areas where action is most required, and can have a valuable role in improving clinical and public health practice.
In Estonia, overall levels of opioid prescribing have increased substantially since 2011 but, despite this increase, indicate the undertreatment of cancer-related pain and potentially some mistreatment in noncancer pain.
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